Compare ALEMBIC PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DIVIS LABORATORIES ALEMBIC PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 21.0 42.2 49.7% View Chart
P/BV x 6.2 8.4 74.3% View Chart
Dividend Yield % 0.6 0.7 83.9%  

Financials

 ALEMBIC PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
ALEMBIC PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6641,639 40.5%   
Low Rs4121,115 37.0%   
Sales per share (Unadj.) Rs208.7186.3 112.0%  
Earnings per share (Unadj.) Rs31.051.0 60.8%  
Cash flow per share (Unadj.) Rs37.157.3 64.7%  
Dividends per share (Unadj.) Rs5.5016.00 34.4%  
Dividend yield (eoy) %1.01.2 88.0%  
Book value per share (Unadj.) Rs144.2261.8 55.1%  
Shares outstanding (eoy) m188.52265.47 71.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.67.4 34.9%   
Avg P/E ratio x17.427.0 64.2%  
P/CF ratio (eoy) x14.524.0 60.4%  
Price / Book Value ratio x3.75.3 70.9%  
Dividend payout %17.731.4 56.5%   
Avg Mkt Cap Rs m101,461365,592 27.8%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m7,4675,423 137.7%   
Avg. sales/employee Rs ThNM4,175.1-  
Avg. wages/employee Rs ThNM457.7-  
Avg. net profit/employee Rs ThNM1,141.8-  
INCOME DATA
Net Sales Rs m39,34749,463 79.5%  
Other income Rs m941,556 6.0%   
Total revenues Rs m39,44151,019 77.3%   
Gross profit Rs m8,73618,718 46.7%  
Depreciation Rs m1,1521,689 68.2%   
Interest Rs m18435 526.0%   
Profit before tax Rs m7,49318,551 40.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5685,023 31.2%   
Profit after tax Rs m5,84413,527 43.2%  
Gross profit margin %22.237.8 58.7%  
Effective tax rate %20.927.1 77.3%   
Net profit margin %14.927.3 54.3%  
BALANCE SHEET DATA
Current assets Rs m19,57746,501 42.1%   
Current liabilities Rs m14,8968,468 175.9%   
Net working cap to sales %11.976.9 15.5%  
Current ratio x1.35.5 23.9%  
Inventory Days Days90131 68.6%  
Debtors Days Days4586 52.8%  
Net fixed assets Rs m27,09725,797 105.0%   
Share capital Rs m377531 71.0%   
"Free" reserves Rs m26,81168,962 38.9%   
Net worth Rs m27,18869,493 39.1%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77880,383 59.4%  
Interest coverage x41.7531.0 7.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.6 133.8%   
Return on assets %12.616.9 74.8%  
Return on equity %21.519.5 110.4%  
Return on capital %23.626.7 88.2%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m19,45341,238 47.2%   
Fx outflow Rs m6,06512,405 48.9%   
Net fx Rs m13,38828,833 46.4%   
CASH FLOW
From Operations Rs m8,1209,543 85.1%  
From Investments Rs m-7,556-6,854 110.2%  
From Financial Activity Rs m590-2,459 -24.0%  
Net Cashflow Rs m1,153230 502.3%  

Share Holding

Indian Promoters % 74.1 52.0 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 11.8 24.6%  
FIIs % 9.1 19.0 47.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.2 80.8%  
Shareholders   49,328 31,796 155.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  TORRENT PHARMA  VENUS REMEDIES  CIPLA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

The Triple Digit Return Opportunity in this Market

Jun 24, 2020

Rahul Shah on stocks with potentially triple digit returns.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - VENUS REMEDIES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS